Clinical trials: Peripheral Vestibular Disorder
Schwannoma, Vestibular, Neurofibromatosis 2
NF2 Natural History Consortium
OBJECTIVES: I. Define the growth rates and clinical course of NF2-related tumors in patients with neurofibromatosis type 2. Associate growth rate with physical function.
- Conditions
- Schwannoma, Vestibular, Neurofibromatosis 2, Meningioma
- Trial name
- NCT00004483
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- House Ear Institute
Vestibular Schwannoma
Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma
Surgical removal of vestibular schwannoma causes acute vestibular symptoms, including postoperative vertigo and oscilopsia due to nystagmus. In general, the dominant symptom postoperatively is vertigo.
- Trial name
- ITG (NCT02963896)
- Testing
- gentamicin
- Volunteers
- 20 people
- Sponsor
- University Hospital, Motol
Vestibular Schwannoma, Acoustic Neuroma
Study of Aspirin in Patients With Vestibular Schwannoma
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
- Conditions
- Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
- Trial name
- NCT03079999
- Testing
- Aspirin
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Neurofibromatosis 2, Vestibular Schwannoma
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
The purpose of this study is to determine if Lapatinib has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2). NF2 is a condition that mainly affects the skin and nervous system.
- Trial name
- NCT00973739
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Neurofibromatosis Type 2, Neuroma, Acoustic
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients.
- Trial name
- NCT01345136
- Testing
- RAD001, everolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Vestibular Schwannoma, Glioma, Astrocytic
USPIO Enhanced MR Imaging in CNS Tumours (UMIC)
The immune response or inflammation is known to be a key driver of progression and growth in many solid tumours. Inflammatory cells called macrophages are present in high numbers in many brain tumours and these tumour associated…
- Trial name
- UMIC (NCT06572475)
- Testing
- USPIO enhanced MRI
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Northern Care Alliance NHS Foundation Trust
Neurofibromatosis Type 2, NF2
Selumetinib for NF2-Related Schwannomatosis
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children…
- Conditions
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma
- Trial name
- ASSIST (NCT07707947)
- Testing
- Selumetinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Migraine, Vestibular Migraine
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
Multiple sensory cues are typically generated by discrete events, and while they do not reach the cerebrum simultaneously, the brain can bind them temporally if they are interpreted as corresponding to a single event.
- Conditions
- Migraine, Vestibular Migraine, Vestibular Schwannoma, Motion Sickness
- Trial name
- NCT04196933
- Testing
- Temporal Binding Adaptation - PSS training, Temporal Binding Adaptation - PSS adaptation with VI stimulation, Chronic Motion-modulated Stimulation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Vestibular Schwannoma, Neurofibromatosis Type 2
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an…
- Trial name
- Endostatin (NCT02104323)
- Testing
- Endostatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Neurofibromatosis Type 2, Vestibular Schwannoma
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with…
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma
- Trial name
- INTUITT-NF2 (NCT04374305)
- Testing
- Brigatinib, Neratinib, Retifanlimab
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Scott R. Plotkin, MD, PhD
Vestibular Schwannoma, Neurofibromatosis Type 2
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
1)Preliminarily evaluate the treatment effect of Icotinib Hydrochloride Tablets on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of Icotinib; 3)Provide an objective basis for an enlarged…
- Trial name
- Icotinib (NCT02934256)
- Testing
- Icotinib
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Li Peng
Neurofibromatosis 2, Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma
- Trial name
- SEL-TH-1601 (NCT03095248)
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Neurofibromatosis Type 2, Vestibular Schwannoma
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
This is an adaptive platform-basket trial that aims to evaluate the safety and efficacy of multiple novel agents and combination therapies in patients with NF2-related schwannomatosis (NF2-SWN).
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma
- Trial name
- PRIME-NF2 (NCT07713745)
- Testing
- Selumetinib 25mg/m2, Luvometinib, Serplulimab
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Beijing Tiantan Hospital
Neurofibromatosis Type 2, Vestibular Schwannoma
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults.
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Acoustic Neuroma
- Trial name
- NF2 (NCT03210285)
- Testing
- Whole exome sequencing
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Tuebingen
Vestibular Schwannoma, Neurofibromatosis Type 2
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
People who have neurofibromatosis type 2 (NF2) can have tumors that grow on the auditory nerves and cause hearing loss. These tumors are called vestibular schwannomas (VSs), or acoustic neuromas.
- Trial name
- NCT01207687
- Testing
- bevacizumab, laboratory biomarker analysis, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Cancer
Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
The overall goal of this study is to attempt to overcome the organizational barriers that impede prompt screening for at-risk sensory deficits in childhood cancer survivors (CCS).
- Trial name
- NCT05582551
- Testing
- Highlighting Patients at Risk for Sensory Screening (HPARSS)
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Washington University School of Medicine
Vestibular Schwannoma, Inner Ear Disease
Vestibular Precision: Physiology & Pathophysiology
This project will investigate the role of noise in the vestibular system, and in particular its effects on the variability (precision) of vestibular-mediated behaviors.
- Conditions
- Vestibular Schwannoma, Inner Ear Disease, Dizziness, Neurofibromatosis 2
- Trial name
- NCT04890132
- Testing
- VOR precision training
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Vestibular Schwannoma
Vestibular Outcomes in Vestibular Schwannoma
Previous studies have shown that vertigo is the symptoms that mostly affect quality of life in patients with vestibular schwannoma.
- Trial name
- VOVS (NCT03346889)
- Where
- Norway
- Volunteers
- 155 people
- Sponsor
- Haukeland University Hospital
Vestibular Schwannoma, Acoustic Neuroma
Auditory Nerve Test System During Vestibular Schwannoma Resection
The Auditory Nerve Test System (ANTS) is a novel device that stimulates the auditory nerve much like a cochlear implant. The purpose of this study is to demonstrate feasibility of the ANTS during translabyrinthine surgery for…
- Conditions
- Vestibular Schwannoma, Acoustic Neuroma, Sensorineural Hearing Loss, Asymmetric Sensorineural Hearing Loss
- Trial name
- ANTS (NCT04241679)
- Testing
- Auditory Nerve Test System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Neurofibromatosis 2
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients.
- Trial name
- AFINF2 (NCT01490476)
- Testing
- RAD001
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris